CellChorus

Emerging

Houston biotech with visual AI TIMING platform analyzing individual cell behaviors in nanowell grids; $5.78M raised plus NIH STTR grant targeting CAR-T quality release and drug discovery screening.

Updated March 2026

Company Overview

About CellChorus

CellChorus is a Houston-based biotechnology company developing the TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) platform — a visual AI system that analyzes individual cell behaviors over time in nanoscale grid arrays to characterize how cells interact, move, and function, enabling drug developers and cell therapy manufacturers to optimize their biologics and cell therapies with unprecedented single-cell resolution. Founded in 2021 and backed with $5.78 million in equity funding plus $3.4 million in non-dilutive grants including a $2.5 million NIH STTR Fast-Track grant in partnership with University of Houston, CellChorus serves biotech researchers, cell therapy manufacturers, and pharmaceutical companies.

Business Model & Competitive Advantage

CellChorus' TIMING platform captures time-lapse microscopy data of individual cells (T-cells, NK cells, CAR-T cells) in nanowell grids and applies computer vision AI to analyze cell-to-cell interactions, killing behaviors, and functional characteristics that static endpoint assays miss. For cell therapy developers (CAR-T, NK cell therapies), this means being able to characterize the potency and killing behavior of manufactured immune cells before infusing them in patients — a quality control capability that current release assays cannot provide. For drug discovery, the platform enables screening drug candidates by their effect on individual cell behavior rather than bulk population averages.

Competitive Landscape 2025–2026

In 2025, CellChorus competes in the cell analysis, bioprocessing analytics, and drug discovery screening market with Sartorius Incucyte (live cell imaging), BioTek Cytation (multimode imaging), and traditional flow cytometry platforms for cell therapy characterization and drug screening. The cell therapy market (CAR-T, NK cell, TIL therapies) has grown significantly with multiple FDA approvals (Kymriah, Yescarta, Carvykti) driving investment in cell therapy manufacturing quality systems. The NIH grant reflects academic validation of the TIMING platform's scientific approach. The 2025 strategy focuses on cell therapy quality release testing partnerships with CDMOs (contract development and manufacturing organizations), expanding the drug discovery screening use case, and building the regulatory science documentation that supports FDA Quality by Design submissions.

Revenue
$5.78M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

CellChorus is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Not So Random Others

Yoneda Labs

Healthcare
HealthtechB2bNorth America

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit

Decoda Health

Healthcare
HealthtechAi PoweredAutomationNorth America

Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap

Fortuna Health

Healthcare
HealthtechB2bAi PoweredAutomationNorth America

Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi

Brisk

Consumer Food & Beverage
B2cManufacturingNorth AmericaFortune500

Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione

Altria

Consumer Goods
B2cManufacturingNorth AmericaPublicFortune500

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s

AbbVie

Healthcare
AnalyticsB2bEnterpriseGlobalHealthtechPublic

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp

Compare CellChorus with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For CellChorus

Claim This Profile

Are you from CellChorus? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim CellChorus Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention CellChorus vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →